1. Home
  2. NVCR vs EVO Comparison

NVCR vs EVO Comparison

Compare NVCR & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • EVO
  • Stock Information
  • Founded
  • NVCR 2000
  • EVO 1993
  • Country
  • NVCR Switzerland
  • EVO Germany
  • Employees
  • NVCR N/A
  • EVO N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVCR Health Care
  • EVO Health Care
  • Exchange
  • NVCR Nasdaq
  • EVO Nasdaq
  • Market Cap
  • NVCR 1.9B
  • EVO 1.5B
  • IPO Year
  • NVCR 2015
  • EVO 2021
  • Fundamental
  • Price
  • NVCR $17.71
  • EVO $4.08
  • Analyst Decision
  • NVCR Buy
  • EVO Buy
  • Analyst Count
  • NVCR 6
  • EVO 2
  • Target Price
  • NVCR $32.83
  • EVO $5.90
  • AVG Volume (30 Days)
  • NVCR 1.6M
  • EVO 116.5K
  • Earning Date
  • NVCR 07-24-2025
  • EVO 08-13-2025
  • Dividend Yield
  • NVCR N/A
  • EVO N/A
  • EPS Growth
  • NVCR N/A
  • EVO N/A
  • EPS
  • NVCR N/A
  • EVO N/A
  • Revenue
  • NVCR $621,711,000.00
  • EVO $851,944,444.00
  • Revenue This Year
  • NVCR $5.56
  • EVO $10.08
  • Revenue Next Year
  • NVCR $9.19
  • EVO $10.99
  • P/E Ratio
  • NVCR N/A
  • EVO N/A
  • Revenue Growth
  • NVCR 18.27
  • EVO 1.50
  • 52 Week Low
  • NVCR $14.17
  • EVO $2.84
  • 52 Week High
  • NVCR $34.13
  • EVO $5.64
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 51.32
  • EVO 57.98
  • Support Level
  • NVCR $17.53
  • EVO $4.15
  • Resistance Level
  • NVCR $18.70
  • EVO $4.35
  • Average True Range (ATR)
  • NVCR 0.72
  • EVO 0.11
  • MACD
  • NVCR 0.09
  • EVO 0.03
  • Stochastic Oscillator
  • NVCR 60.56
  • EVO 98.39

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: